Literature DB >> 20812000

Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.

William E Tidyman1, Katherine A Rauen.   

Abstract

The Ras/mitogen-activated protein kinase (MAPK) pathway is essential in regulation of the cell cycle, cell differentiation, growth, and cell senescence, each of which are critical to normal development. A class of developmental disorders, the "RASopathies," is caused by germline mutations in genes that encode protein components of the Ras/MAPK pathway which result in dysregulation of the pathway and profound deleterious effects on development. One of these syndromes, cardiofaciocutaneous (CFC) syndrome, is caused by germline mutations in BRAF, MAP2K1 (MEK1) and MAP2K2 (MEK2), and possibly KRAS genes. Here, we describe the laboratory protocols and methods that we used to identify mutations in BRAF and MEK1/2 genes as causative for CFC syndrome. In addition, we present the techniques used to determine the effect these mutations have on activity of the Ras/MAPK pathway through Western blot analysis of the phosphorylation of endogenous ERK1/2, as well as through the use of an in vitro kinase assay that measures the phosphorylation of Elk-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20812000     DOI: 10.1007/978-1-60761-795-2_27

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development.

Authors:  D H Siegel; J A Mann; A L Krol; K A Rauen
Journal:  Br J Dermatol       Date:  2012-03       Impact factor: 9.302

2.  Comprehensive Genetic Analysis of RASopathy in the Era of Next-Generation Sequencing and Definition of a Novel Likely Pathogenic >KRAS Variation.

Authors:  Selma Demir; Hümeyra Yaşar Köstek; Aslıhan Sanrı; Ruken Yıldırım; Fatma Özgüç Çömlek; Sinem Yalçıntepe; Murat Deveci; Emine İkbal Atlı; Engin Atlı; Damla Eker; Hakan Gürkan; Filiz Tütüncüler Kökenli
Journal:  Mol Syndromol       Date:  2022-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.